Abstract: A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component (“PFC”) and a nucleic acid-like component (“NAC”) in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water.

Abstract: A phospholipid derivative represented by the following formula (1) wherein each symbol is as described in the specification; a liposome containing the phospholipid derivative, and the like.

Abstract: Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same.

Abstract: Method for the preparation of nano- and mesosized particles consisting of a lipid layer comprising at least one amphiphile and a core of an inorganic compound and/or a metal, comprising: (i) dissolving in a common solvent at least one self-aggregating amphiphile with at least one inorganic, organometallic or metallorganic precursor of said inorganic compound or metal; and (ii) either injecting the resulting solution into an aqueous solution or drying the resulting solution and re-hydrating it, so as to form particles in which the precursor is encapsulated by the amphiphile(s) and is converted therein to said inorganic compound and/or metallic solid form.

Abstract: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. The subject phase invertible compositions are prepared by combining a proteinaceous substrate and a crosslinking agent, such as a stabilized aldehyde crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Abstract: A stanol composition containing in addition to sitostanol as the main component, also a substantial amount of at least 10% campestanol has been found to effectively lower serum cholesterol levels when incorporated in edible commodities. Upon esterification the composition is especially useful in edible fats and oils and in fat-containing foods.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induced premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation.

Abstract: This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are also disclosed in treatment of environmentally caused premature skin aging, via reductions in fine facial lines and wrinkles, increased tensile strength of the skin, and increased protection against sunlight via increased production of melanin. Therapeutic outcomes are improved when the copper-pigment complex is enclosed within submicron liposomes.

Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.

Abstract: Provided herein are compositions and methods for delivery of nucleic acids to individuals and to cells, including nucleic acid delivery particles that comprising a lipid-binding polypeptide, a lipid bilayer comprising one or more cationic lipids, and a nucleic acid.

Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Abstract: The present invention provides formulations containing at least one unsaturated amphiphilic lipid and an amphipathic or hydrophobic drug and methods of making these formulations. In particular, the present invention provides formulations of at least one unsaturated phospholipid and an amphipathic or hydrophobic pyrimidine drug, methods of making these formulations and the use of such formulations in a variety of contexts, including, for example, the treatment of proliferative disorders, such as tumors and cancers.

Abstract: The present invention relates to methods and compositions for the treatment of cancer and for research and analysis of cancer. In particular, the present invention provides encapsulated arsenic anti-cancer compositions with improved properties.

Abstract: The invention concerns a composition containing at least an oxazolin, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an alkanolamide, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such composition on the skin and/or mucosa.

Abstract: This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) gemcitabine and (b) C6-ceramide, sequentially or concomitantly, wherein the gemcitabine and C6-ceramide are in amounts such that the apoptosis induced by the combination of gemcitabine and C6-ceramide is greater than the apoptosis induced by contacting the cancer cell with either gemcitabine alone or C6-ceramide alone. This invention also provides a method of decreasing the size of a tumor, which method comprises contacting the tumor with (a) gemcitabine and (b) C6-ceramide, sequentially or concomitantly, wherein the gemcitabine and C6-ceramide are in amounts such that the decrease in tumor size induced by the combination of gemcitabine and C6-ceramide is greater than the decrease in tumor size induced by contacting the tumor with either gemcitabine alone or C6-ceramide alone.

Abstract: The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.

Abstract: A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly suitable for pulmonary delivery for therapeutic and other purposes may be prepared.

Abstract: The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of ‘triple receptor negative’ breast cancer.